{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:41:32Z","timestamp":1765291292466,"version":"3.46.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Science and Technology Commission of Shanghai Municipality","award":["23S11900400 and 23ZR1439900"],"award-info":[{"award-number":["23S11900400 and 23ZR1439900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-025-00803-y","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:36:43Z","timestamp":1765291003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic and clinical characterization of two families with severe venous thromboembolism due to nonsense mutations in the SERPINC1 gene"],"prefix":"10.1186","volume":"23","author":[{"given":"Xuqian","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"803_CR1","doi-asserted-by":"publisher","unstructured":"Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20:248\u2013262. https:\/\/doi.org\/10.1038\/s41569-022-00787-6.","DOI":"10.1038\/s41569-022-00787-6"},{"key":"803_CR2","doi-asserted-by":"publisher","unstructured":"Lindstr\u00f6m S, Wang L, Smith EN, et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood. 2019;134:1645\u20131657. https:\/\/doi.org\/10.1182\/blood.2019000435.","DOI":"10.1182\/blood.2019000435"},{"key":"803_CR3","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.V82.8.2423.2423","volume":"82","author":"B Lind","year":"1993","unstructured":"Lind B, van Solinge WW, Schwartz M, et al. Splice site mutation in the human protein C gene associated with venous thrombosis: demonstration of exon skipping by ectopic transcript analysis. Blood. 1993;82:2423\u201332.","journal-title":"Blood"},{"key":"803_CR4","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1182\/blood.2023023326","volume":"143","author":"J Ryu","year":"2024","unstructured":"Ryu J, R\u00e4m\u00f6 JT, Jurgens SJ, et al. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK biobank. Blood. 2024;143:2425\u201332. https:\/\/doi.org\/10.1182\/blood.2023023326.","journal-title":"Blood"},{"key":"803_CR5","doi-asserted-by":"publisher","first-page":"102157","DOI":"10.1016\/j.rpth.2023.102157","volume":"7","author":"XJ Zhu","year":"2023","unstructured":"Zhu XJ, Liu ZY, Wang PW, et al. Congenital thrombophilia in East-Asian venous thromboembolism population: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2023;7:102157. https:\/\/doi.org\/10.1016\/j.rpth.2023.102157.","journal-title":"Res Pract Thromb Haemost"},{"key":"803_CR6","doi-asserted-by":"publisher","unstructured":"Wolberg AS, Rosendaal FR, Weitz JI, et al. Venous thrombosis. Nat Rev Dis Primers. 2015;1:15006. https:\/\/doi.org\/10.1038\/nrdp.2015.6.","DOI":"10.1038\/nrdp.2015.6"},{"key":"803_CR7","doi-asserted-by":"publisher","unstructured":"Alnor AB, Gils C, Vinholt PJ. Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis. Ann Hematol. 2024;103:4285\u20134294. https:\/\/doi.org\/10.1007\/s00277-024-05926-2.","DOI":"10.1007\/s00277-024-05926-2"},{"key":"803_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2141.2009.07786.x","volume":"146","author":"LN Roberts","year":"2009","unstructured":"Roberts LN, Patel RK, Arya R. Venous thromboembolism and ethnicity. Br J Haematol. 2009;146:369\u201383. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07786.x.","journal-title":"Br J Haematol"},{"key":"803_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11239-013-1005-x","volume":"37","author":"T Yin","year":"2014","unstructured":"Yin T, Miyata T. Dysfunction of protein C anticoagulant system, main genetic risk factor for venous thromboembolism in Northeast Asians. J Thromb Thrombolysis. 2014;37:56\u201365. https:\/\/doi.org\/10.1007\/s11239-013-1005-x.","journal-title":"J Thromb Thrombolysis"},{"key":"803_CR10","doi-asserted-by":"publisher","unstructured":"Lai SW, Chang CY, Lee HJ, et al. Identification of two point mutations associated with inherited antithrombin deficiency. Thromb J. 2024;22:107. https:\/\/doi.org\/10.1186\/s12959-024-00677-6.","DOI":"10.1186\/s12959-024-00677-6"},{"key":"803_CR11","doi-asserted-by":"publisher","unstructured":"Biswas I, Panicker SR, Lupu F, et al. Physiological significance of antithrombin D-helix interaction with vascular GAGs. Blood Adv. 2025;9:966\u2013978. https:\/\/doi.org\/10.1182\/bloodadvances.2024014756.","DOI":"10.1182\/bloodadvances.2024014756"},{"key":"803_CR12","doi-asserted-by":"publisher","unstructured":"Jin L, Abrahams JP, Skinner R, et al. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA. 1997;94:14683\u201314688. https:\/\/doi.org\/10.1073\/pnas.94.26.14683.","DOI":"10.1073\/pnas.94.26.14683"},{"key":"803_CR13","doi-asserted-by":"publisher","unstructured":"Shworak NW, Kobayashi T, de Agostini A, et al. Anticoagulant heparan sulfate to not clot-or not? Prog Mol Biol Transl Sci. 2010;93:153\u2013178. https:\/\/doi.org\/10.1016\/S1877-1173(10)93008-1.","DOI":"10.1016\/S1877-1173(10)93008-1"},{"key":"803_CR14","doi-asserted-by":"publisher","unstructured":"Olson ST, Richard B, Izaguirre G, et al. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie. 2010;92:1587\u20131596. https:\/\/doi.org\/10.1016\/j.biochi.2010.05.011.","DOI":"10.1016\/j.biochi.2010.05.011"},{"key":"803_CR15","doi-asserted-by":"publisher","unstructured":"Gettins PGW. Serpin structure, mechanism, and function. Chem Rev. 2002;102:4751\u20134804. https:\/\/doi.org\/10.1021\/cr010170+.","DOI":"10.1021\/cr010170+"},{"key":"803_CR16","doi-asserted-by":"publisher","unstructured":"Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature. 1973;246:355\u2013357. https:\/\/doi.org\/10.1038\/246355a0.","DOI":"10.1038\/246355a0"},{"key":"803_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1055\/s-0038-1657579","volume":"78","author":"R Carrell","year":"1997","unstructured":"Carrell R, Skinner R, Jin L, et al. Structural mobility of antithrombin and its modulation by heparin. Thromb Haemost. 1997;78:516\u20139.","journal-title":"Thromb Haemost"},{"key":"803_CR18","doi-asserted-by":"publisher","unstructured":"Bravo-P\u00e9rez C, Corral J, Orlando C, et al. How we treat severe inherited antithrombin deficiency: lessons from cases homozygous for the Budapest 3 variant. J Thromb Haemost. 2025;23:1648\u20131656. https:\/\/doi.org\/10.1016\/j.jtha.2025.01.015.","DOI":"10.1016\/j.jtha.2025.01.015"},{"key":"803_CR19","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.jtha.2024.06.004","volume":"22","author":"M Underwood","year":"2024","unstructured":"Underwood M, Bidlack C, Desch KC. Venous thromboembolic disease genetics: from variants to function. J Thromb Haemost. 2024;22:2393\u2013403. https:\/\/doi.org\/10.1016\/j.jtha.2024.06.004.","journal-title":"J Thromb Haemost"},{"key":"803_CR20","doi-asserted-by":"publisher","unstructured":"Corral J, de la Morena-Barrio ME, Vicente V. The genetics of antithrombin. Thromb Res. 2018;169:23\u201329. https:\/\/doi.org\/10.1016\/j.thromres.2018.07.008.","DOI":"10.1016\/j.thromres.2018.07.008"},{"key":"803_CR21","doi-asserted-by":"publisher","unstructured":"Lane DA, Kunz G, Olds RJ, et al. Molecular genetics of antithrombin deficiency. Blood Rev. 1996;10:59\u201374. https:\/\/doi.org\/10.1016\/s0268-960x(96)90034-x.","DOI":"10.1016\/s0268-960x(96)90034-x"},{"key":"803_CR22","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3390\/ijms25052893","volume":"25","author":"J K\u00e1llai","year":"2024","unstructured":"K\u00e1llai J, Gindele R, P\u00e9nzes-Daku K, et al. Clinical and molecular characterization of nine novel antithrombin mutations. Int J Mol Sci. 2024;25:2893. https:\/\/doi.org\/10.3390\/ijms25052893.","journal-title":"Int J Mol Sci"},{"key":"803_CR23","doi-asserted-by":"publisher","unstructured":"Cooper PC, Coath F, Daly ME, et al. The phenotypic and genetic assessment of antithrombin deficiency. Int J Lab Hematol. 2011;33:227\u201337. https:\/\/doi.org\/10.1111\/j.1751-553X.2011.01307.x.","DOI":"10.1111\/j.1751-553X.2011.01307.x"},{"key":"803_CR24","doi-asserted-by":"publisher","unstructured":"Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377:1177\u201387. https:\/\/doi.org\/10.1056\/NEJMra1700365.","DOI":"10.1056\/NEJMra1700365"},{"key":"803_CR25","doi-asserted-by":"publisher","unstructured":"Olson SR, Shatzel JJ, DeLoughery TG. Asymptomatic breakthrough thrombosis and anticoagulant failure: keep calm and carry on. Res Pract Thromb Haemost. 2019;3:498\u2013502. https:\/\/doi.org\/10.1002\/rth2.12218.","DOI":"10.1002\/rth2.12218"},{"key":"803_CR26","doi-asserted-by":"publisher","unstructured":"Li W, Johnson DJD, Esmon CT, et al. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol. 2004;11:857\u2013862. https:\/\/doi.org\/10.1038\/nsmb811.","DOI":"10.1038\/nsmb811"},{"key":"803_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1160\/TH10-08-0538","volume":"105","author":"B Luxembourg","year":"2011","unstructured":"Luxembourg B, Delev D, Geisen C, et al. Molecular basis of antithrombin deficiency. Thromb Haemost. 2011;105:635\u201346. https:\/\/doi.org\/10.1160\/TH10-08-0538.","journal-title":"Thromb Haemost"},{"key":"803_CR28","doi-asserted-by":"publisher","unstructured":"Gandrille S, Vidaud D, Emmerich J, et al. Molecular basis for hereditary antithrombin III quantitative deficiencies: a stop codon in exon IIIa and a frameshift in exon VI. Br J Haematol. 1991;78:414\u2013420. https:\/\/doi.org\/10.1111\/j.1365-2141.1991.tb04457.x.","DOI":"10.1111\/j.1365-2141.1991.tb04457.x"},{"key":"803_CR29","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1111\/jth.12364","volume":"11","author":"M Puurunen","year":"2013","unstructured":"Puurunen M, Salo P, Engelbarth S, et al., et al. Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture. J Thromb Haemost. 2013;11:1844\u20139. https:\/\/doi.org\/10.1111\/jth.12364.","journal-title":"J Thromb Haemost"},{"key":"803_CR30","doi-asserted-by":"publisher","unstructured":"Wessler S. Estrogen-associated thromboembolism. Ann Epidemiol. 1992;2:439\u2013443. https:\/\/doi.org\/10.1016\/1047-2797(92)90093-6.","DOI":"10.1016\/1047-2797(92)90093-6"},{"key":"803_CR31","doi-asserted-by":"publisher","unstructured":"Van Cott EM, Orlando C, Moore GW, et al. Recommendations for clinical laboratory testing for antithrombin deficiency; communication from the SSC of the ISTH. J Thromb Haemost. 2020;18:17\u201322. https:\/\/doi.org\/10.1111\/jth.14648.","DOI":"10.1111\/jth.14648"},{"key":"803_CR32","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1182\/blood.V92.8.2696","volume":"92","author":"NJ Beauchamp","year":"1998","unstructured":"Beauchamp NJ, Pike RN, Daly M, et al. Antithrombins Wibble and wobble (T85M\/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood. 1998;92:2696\u2013706.","journal-title":"Blood"},{"key":"803_CR33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1055\/s-0037-1616528","volume":"86","author":"AC Fitches","year":"2001","unstructured":"Fitches AC, Lewandowski K, Olds RJ. Creation of an additional glycosylation site as a mechanism for type I antithrombin deficiency. Thromb Haemost. 2001;86:1023\u20137.","journal-title":"Thromb Haemost"},{"key":"803_CR34","doi-asserted-by":"publisher","unstructured":"Corral J, Huntington JA, Gonz\u00e1lez-Conejero R, et al. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost. 2004;2:931\u2013939. https:\/\/doi.org\/10.1111\/j.1538-7836.2004.00749.x.","DOI":"10.1111\/j.1538-7836.2004.00749.x"},{"key":"803_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.abb.2010.08.021","volume":"504","author":"S Schedin-Weiss","year":"2010","unstructured":"Schedin-Weiss S, Richard B, Olson ST. Kinetic evidence that allosteric activation of antithrombin by heparin is mediated by two sequential conformational changes. Arch Biochem Biophys. 2010;504:169\u201376. https:\/\/doi.org\/10.1016\/j.abb.2010.08.021.","journal-title":"Arch Biochem Biophys"},{"key":"803_CR36","doi-asserted-by":"publisher","unstructured":"Izaguirre G, Aguila S, Qi L, et al. Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease. J Biol Chem. 2014;289:34049\u201334064. https:\/\/doi.org\/10.1074\/jbc.M114.611707.","DOI":"10.1074\/jbc.M114.611707"},{"key":"803_CR37","first-page":"15","volume":"53","author":"R Verhaeghe","year":"1998","unstructured":"Verhaeghe R. The use of low-molecular-weight heparins in cardiovascular disease. Acta Cardiol. 1998;53:15\u201321.","journal-title":"Acta Cardiol"},{"key":"803_CR38","doi-asserted-by":"publisher","unstructured":"Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg. 2008;85:2153\u201360. https:\/\/doi.org\/10.1016\/j.athoracsur.2008.02.037.","DOI":"10.1016\/j.athoracsur.2008.02.037"},{"key":"803_CR39","doi-asserted-by":"publisher","unstructured":"Takeuchi F, Ebuchi Y, Saito Y, et al. Rivaroxaban for venous thrombosis in a patient with congenital antithrombin deficiency. Int Heart J. 2024;65:1182\u20131185. https:\/\/doi.org\/10.1536\/ihj.24-370.","DOI":"10.1536\/ihj.24-370"},{"key":"803_CR40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jccase.2017.06.008","volume":"16","author":"J Yamaguchi","year":"2017","unstructured":"Yamaguchi J, Hara N, Yamaguchi T, et al. Successful treatment of a massive pulmonary embolism using Rivaroxaban in a patient with antithrombin III deficiency. J Cardiol Cases. 2017;16:144\u20137. https:\/\/doi.org\/10.1016\/j.jccase.2017.06.008.","journal-title":"J Cardiol Cases"},{"key":"803_CR41","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.2169\/internalmedicine.55.7314","volume":"55","author":"H Kawano","year":"2016","unstructured":"Kawano H, Maemura K. Edoxaban was effective for the treatment of deep vein thrombosis and pulmonary thromboembolism in a cancer patient with antithrombin III deficiency. Intern Med. 2016;55:3285\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.55.7314.","journal-title":"Intern Med"},{"key":"803_CR42","doi-asserted-by":"publisher","unstructured":"May JE, Moll S. How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both? Blood. 2024;143:2351\u20132362. https:\/\/doi.org\/10.1182\/blood.2023021638.","DOI":"10.1182\/blood.2023021638"},{"key":"803_CR43","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","volume":"366","author":"C Becattini","year":"2012","unstructured":"Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1114238.","journal-title":"N Engl J Med"},{"key":"803_CR44","doi-asserted-by":"publisher","unstructured":"Steele P, Ellis J Jr., Genton E. Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. Am J Med. 1978;64:441\u2013445. https:\/\/doi.org\/10.1016\/0002-9343(78)90230-9.","DOI":"10.1016\/0002-9343(78)90230-9"},{"key":"803_CR45","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","volume":"355","author":"Prevention of pulmonary embolism","year":"2000","unstructured":"Prevention of pulmonary embolism. And deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet. 2000;355:1295\u2013302.","journal-title":"Lancet"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00803-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00803-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00803-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:36:44Z","timestamp":1765291004000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-025-00803-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00803-y","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures of this study were performed in compliance with relevant laws and institutional guidelines. And this work was approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital (2025-KY-123). The two subjects and their families involved in this study fully supported this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}